BioGaia has extended its collaboration with the Swiss pharmaceutical company Ewopharma AG giving the company exclusive rights to sell BioGaia's Probiotic Drops and Tablets, under the BioGaia trademark, in Serbia and Croatia.
"We are very pleased to see the continued expansion in Central Eastern Europe (CEE). The combination of Ewopharma's solid presence in CEE and BioGaia's products based on strong scientific documentation, has proven to be a success." says Peter Rothschild, President, BioGaia AB. "We look forward to successful product launches during 2009."
"In light of the positive sales growth in our CEE countries, we are eager to launch BioGaia drops and tablets in Serbia and Croatia" says Martin Hongler, Vice President at Ewopharma. "The demand for BioGaia's products is growing steadily in our markets and the increasing scientific documentation in several indication areas continue to impress".
Ewopharma AG is a privately held Swiss company of 50 years experience, active on the pharmaceutical markets in Central Eastern Europe. It has its headquarters in Schaffhausen (Switzerland) and local subsidiaries in most CEE countries.
For additional information contact: Peter Rothschild, Managing Director, telephone: +46 8 - 555 293 00,
Jan Annwall deputy Managing Director telephone: +46 8 - 555 293 00
BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the Nordic Stock Exchange in Stockholm.